Skip to content
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Neurology · Behavioral Variant Frontotemporal Dementia

What Medications Help Behavioral Symptoms in bvFTD?

At a Glance

There is no FDA-approved medication specifically for bvFTD. After reversible medical causes are checked and non-drug strategies are tried, clinicians may cautiously use off-label SSRIs or trazodone; antipsychotics are reserved for severe situations because of serious risks.

When someone with behavioral variant frontotemporal dementia (bvFTD)—a condition causing profound changes in personality, impulsivity, apathy, and disinhibition—exhibits distressed, aggressive, or unsafe behavior, families often desperately seek medication options. While non-drug methods are always the first line of defense, medications are sometimes considered to manage specific symptoms. Because there are no FDA-approved drugs specifically for bvFTD, doctors use medications “off-label,” relying on limited trial evidence and clinical experience [1][2].

The Crucial First Step: Rule Out Medical Causes

Before starting any psychiatric medication for a sudden or worsening behavior change, a doctor should evaluate the person for underlying, reversible medical causes [3][4]. Often, an abrupt change in behavior is actually delirium caused by pain, an infection (such as a urinary tract infection), constipation, urinary retention, poor sleep, or a medication interaction [3]. If the behavior presents a sudden, immediate physical danger, families should seek local emergency or crisis help rather than waiting for an outpatient medication trial.

Non-drug approaches—such as maintaining predictable routines, reducing environmental noise, redirecting the person rather than arguing, and making the home safer—remain the foundation of care [5]. However, when these approaches are insufficient and reversible causes are ruled out, certain medications may be considered.

Off-Label Options Often Considered: SSRIs and Trazodone

Clinicians often consider Selective Serotonin Reuptake Inhibitors (SSRIs) and trazodone when a medication trial is necessary [6][2]. It is hypothesized that because bvFTD heavily impacts the frontal lobes—areas of the brain that utilize the neurotransmitter serotonin—medications targeting serotonin networks might help, though the exact reasons they benefit some individuals remain poorly understood and the clinical evidence is limited [6].

  • SSRIs (such as sertraline and citalopram): Doctors frequently prescribe SSRIs to target specific issues like disinhibition (acting impulsively without regard for social norms), hyperorality (compulsive eating or putting objects in the mouth), and repetitive behaviors [6][7]. It is important to know that SSRIs are not interchangeable. For example, while paroxetine is sometimes used, it has strong anticholinergic effects that can worsen cognition and constipation [6][8]. Citalopram carries risks for heart rhythm changes (QT prolongation) and may require an ECG [9]. Any SSRI can cause side effects like nausea, sleep changes, low sodium, bleeding risks, or an early worsening of agitation [6].
  • Trazodone: Originally developed as an antidepressant, trazodone may help reduce some behavioral symptoms, particularly impulsivity and sleep disturbances, though the supporting evidence comes mostly from small studies [6]. Trazodone can cause significant sedation; caregivers must be careful not to mistake drug-induced sleepiness for actual improvement in the core behavior [10]. It also carries risks for dizziness, orthostatic hypotension (a sudden drop in blood pressure when standing up), and an increased risk of falls [11][10].

The Dangers of Antipsychotics

When behaviors include severe distress, psychosis, or persistent aggression, families and doctors may discuss antipsychotic medications (such as risperidone, olanzapine, or quetiapine). These drugs come with severe risks for people with dementia and must be approached with extreme caution [12][13].

  • Black-Box Warning: In the United States, all antipsychotic medications carry a strict regulatory class warning (a “black-box warning”) alerting that they are associated with an increased risk of death when used in elderly patients with dementia-related psychosis or behavioral disturbances [14][13].
  • Stroke and Cerebrovascular Events: Antipsychotics significantly increase the risk of cerebrovascular events, including strokes [13].
  • Severe Movement Side Effects: These drugs can cause extrapyramidal symptoms, which are serious drug-induced movement disorders [15]. These include parkinsonism (tremors, severe stiffness, a shuffling gait), severe restlessness (akathisia), and involuntary muscle movements, which can severely compromise the person’s mobility, comfort, and ability to swallow [15][16].
  • When They Are Considered: Clinical guidelines suggest antipsychotics should be considered a time-limited option only for severe distress, psychosis, or persistent severe aggression with a substantial risk of harm, and only after medical causes and non-drug approaches have been fully addressed [3][4]. Prescribing them requires a discussion about informed consent, a specific behavioral target, the lowest effective dose, and scheduled reassessment [17].

Medications Usually Avoided

It is equally important to know what is generally not recommended. Drugs used to treat Alzheimer’s disease memory symptoms (like cholinesterase inhibitors or memantine) have not shown benefit in bvFTD and may actually worsen behavioral symptoms [1]. Likewise, benzodiazepines or strongly anticholinergic drugs can worsen confusion, significantly increase fall risk, and sometimes cause paradoxical disinhibition—making the behavior worse instead of better [8].

Strategy, Monitoring, and Emergencies

Medication trials in bvFTD require careful monitoring and a close partnership with your doctor.

  • Target Specific Behaviors: A medication trial works best when tracking a specific, measurable behavior (such as compulsive pacing or aggressive outbursts during dressing) rather than a vague complaint of general “agitation” [6].
  • Start Low, Go Slow: Dosing must account for the person’s age, frailty, kidney or liver function, fall history, and other medications [18]. SSRIs may take several weeks to show a behavioral benefit, while sedating side effects can appear immediately [6].
  • When to Taper vs. When to Seek Urgent Help: If a medication isn’t working or is causing mild side effects like daytime drowsiness, work with the prescriber to gradually taper it off [5][19]. However, do not wait for a scheduled tapering appointment if emergency signs appear. Seek prompt medical help for fainting, new one-sided weakness, facial droop, trouble speaking, severe stiffness accompanied by fever, inability to swallow, severe rash, or sudden dangerous sedation [13][15].

Common questions in this guide

What medications are usually tried for behavioral symptoms in bvFTD?
No medication is FDA-approved specifically for bvFTD. When non-drug strategies are not enough and medical causes have been ruled out, clinicians may try an SSRI such as sertraline or citalopram, or trazodone, for a use not specifically approved for bvFTD. Evidence is limited, and the choice depends on the person’s health, other medicines, and behavior target.
Could an SSRI help with disinhibition or repetitive behavior in bvFTD?
Clinicians sometimes use SSRIs such as sertraline or citalopram for disinhibition, repetitive behaviors, or hyperorality. They may take several weeks to help and can cause nausea, sleep changes, low sodium, bleeding, or early worsening of agitation. Citalopram may affect heart rhythm, and paroxetine may worsen cognition or constipation because of its anticholinergic effects.
Is trazodone an option for bvFTD behavior and sleep problems?
Trazodone may reduce impulsivity or help sleep in some people, but evidence comes mostly from small studies. It can cause marked sleepiness, dizziness, a drop in blood pressure on standing, and falls. Sleepiness should not be assumed to mean the underlying behavior has improved.
When are antipsychotics considered for someone with bvFTD?
Antipsychotics such as risperidone, olanzapine, or quetiapine are generally considered only for severe distress, psychosis, or persistent severe aggression when there is a substantial risk of harm and other approaches have not worked. In people with dementia, these drugs carry an increased risk of death and stroke, as well as serious movement problems. If used, the prescriber should define a target, use the lowest effective dose, and reassess on a schedule.
What should happen before medication is started after a sudden behavior change?
A sudden or worsening behavior change should prompt a medical check for reversible causes such as pain, infection, constipation, urinary retention, poor sleep, delirium, or a medication interaction. Families should address these causes and try non-drug measures such as a predictable routine, less noise, redirection, and improved safety when possible. If the person poses immediate physical danger, seek local emergency or crisis help rather than waiting for a medication trial.
How can we tell whether a bvFTD medication is working?
Choose one specific, measurable behavior—such as pacing or aggressive outbursts during dressing—and track how often and how severe it is. Side effects such as sedation may appear immediately, while an SSRI may take several weeks to show benefit. Work with the prescriber to review the trial and taper medication gradually if it is not helping or is causing problems.
Which medication side effects require urgent medical help?
Seek prompt medical help for fainting, new one-sided weakness, facial drooping, trouble speaking, severe stiffness with fever, inability to swallow, a severe rash, or sudden dangerous sedation. These can signal a serious reaction, stroke, or movement complication. Do not wait for a routine medication review when these signs occur.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific behavior are we trying to target with this medication, and how will we measure if it is working?
  2. 2.What are the potential side effects, and are there specific warning signs (like increased fall risk, dizziness, or movement issues) that I should monitor for?
  3. 3.How does this medication interact with the person's other health conditions and current prescriptions?
  4. 4.What is our timeline for trying this medication, and when will we schedule an evaluation to see if we should taper it down?
  5. 5.Who should I call after hours if the person's behavior becomes suddenly unsafe or if they experience a concerning reaction?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Treatment of the behavioral variant of frontotemporal dementia: a narrative review.

    Gambogi LB, Guimarães HC, de Souza LC, Caramelli P

    Dementia & neuropsychologia 2021; (15(3)):331-338 doi:10.1590/1980-57642021dn15-030004.

    PMID: 34630920
  2. 2

    Expert opinions on pharmacological symptomatic treatment of behavioral symptoms in frontotemporal dementia: A survey of the Neuropsychiatric International Consortium on Frontotemporal Dementia (NIC-FTD).

    van Paassen D, Hartog L, de Boer S, et al.

    European journal of neurology 2025; (32(1)):e16537 doi:10.1111/ene.16537.

    PMID: 39607834
  3. 3

    Management of Behavioral and Psychological Symptoms of Dementia.

    Bessey LJ, Walaszek A

    Current psychiatry reports 2019; (21(8)):66 doi:10.1007/s11920-019-1049-5.

    PMID: 31264056
  4. 4

    Pharmacotherapy of Behavioral and Psychological Symptoms of Dementia: State of the Art and Future Progress.

    Magierski R, Sobow T, Schwertner E, Religa D

    Frontiers in pharmacology 2020; (11()):1168 doi:10.3389/fphar.2020.01168.

    PMID: 32848775
  5. 5

    A European Academy of Neurology guideline on medical management issues in dementia.

    Frederiksen KS, Cooper C, Frisoni GB, et al.

    European journal of neurology 2020; (27(10)):1805-1820 doi:10.1111/ene.14412.

    PMID: 32713125
  6. 6

    Effectiveness of Pharmacological Interventions for Symptoms of Behavioral Variant Frontotemporal Dementia: A Systematic Review.

    Trieu C, Gossink F, Stek ML, et al.

    Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology 2020; (33(1)):1-15 doi:10.1097/WNN.0000000000000217.

    PMID: 32132398
  7. 7

    Citalopram Improves Obsessive-Compulsive Crossword Puzzling in Frontotemporal Dementia.

    Meyer S, Mueller K, Gruenewald C, et al.

    Case reports in neurology 2019; (11(1)):94-105 doi:10.1159/000495561.

    PMID: 31011326
  8. 8

    Trends in Psychotropic Dispensing Among Older Adults with Dementia Living in Long-Term Care Facilities: 2004-2013.

    Vasudev A, Shariff SZ, Liu K, et al.

    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2015; (23(12)):1259-1269 doi:10.1016/j.jagp.2015.07.001.

    PMID: 26525997
  9. 9

    [Trazodone in psychogeriatric care].

    Gahr M, Merz B

    Fortschritte der Neurologie-Psychiatrie 2025; doi:10.1055/a-2600-3773.

    PMID: 40550256
  10. 10

    Treatment Efficacy of Pharmacotherapies for Frontotemporal Dementia: A Network Meta-Analysis of Randomized Controlled Trials.

    Huang MH, Zeng BS, Tseng PT, et al.

    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2023; (31(12)):1062-1073 doi:10.1016/j.jagp.2023.06.013.

    PMID: 37633762
  11. 11

    Comparative risk of harm associated with trazodone or atypical antipsychotic use in older adults with dementia: a retrospective cohort study.

    Watt JA, Gomes T, Bronskill SE, et al.

    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2018; (190(47)):E1376-E1383 doi:10.1503/cmaj.180551.

    PMID: 30478215
  12. 12

    Management of behavioural and psychological symptoms of dementia: a pragmatic scoping review of European guidelines and literature.

    Coin A, Brew-Girard E, Tracey E, et al.

    European geriatric medicine 2025; (16(3)):753-770 doi:10.1007/s41999-025-01155-6.

    PMID: 39969801
  13. 13

    Assessment of Reported Comparative Effectiveness and Safety of Atypical Antipsychotics in the Treatment of Behavioral and Psychological Symptoms of Dementia: A Network Meta-analysis.

    Yunusa I, Alsumali A, Garba AE, et al.

    JAMA network open 2019; (2(3)):e190828 doi:10.1001/jamanetworkopen.2019.0828.

    PMID: 30901041
  14. 14

    Mortality Risk of Atypical Antipsychotics for Behavioral and Psychological Symptoms of Dementia: A Meta-Analysis, Meta-Regression, and Trial Sequential Analysis of Randomized Controlled Trials.

    Yeh TC, Tzeng NS, Li JC, et al.

    Journal of clinical psychopharmacology 2019; (39(5)):472-478 doi:10.1097/JCP.0000000000001083.

    PMID: 31433335
  15. 15

    Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia.

    Mühlbauer V, Möhler R, Dichter MN, et al.

    The Cochrane database of systematic reviews 2021; (12()):CD013304 doi:10.1002/14651858.CD013304.pub2.

    PMID: 34918337
  16. 16

    An Evidence-Based Update on Anticholinergic Use for Drug-Induced Movement Disorders.

    Vanegas-Arroyave N, Caroff SN, Citrome L, et al.

    CNS drugs 2024; (38(4)):239-254 doi:10.1007/s40263-024-01078-z.

    PMID: 38502289
  17. 17

    New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer's disease: focus on brexpiprazole and pimavanserin.

    Caraci F, Santagati M, Caruso G, et al.

    F1000Research 2020; (9()) doi:10.12688/f1000research.22662.1.

    PMID: 32695312
  18. 18

    Daytime sleepiness is independently associated with falls in older adults with dementia.

    Chen PY, Chiu HT, Chiu HY

    Geriatrics & gerontology international 2016; (16(7)):850-5 doi:10.1111/ggi.12567.

    PMID: 26245804
  19. 19

    Dealing with behavioral and psychological symptoms of dementia: a general overview.

    Azermai M

    Psychology research and behavior management 2015; (8()):181-5 doi:10.2147/PRBM.S44775.

    PMID: 26170729

This page explains medication options for behavioral symptoms in bvFTD for informational purposes only and does not constitute medical advice. A prescribing clinician should tailor and monitor any medication trial.

Get notified when new evidence is published on Behavioral variant of frontotemporal dementia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.